DGAP-News: Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.